Atrial fibrillation (AFib) is a common cardiac arrhythmia estimated to affect about 52.55 million people globally. People with AFib have a higher risk of complications such as stroke, heart failure, myocardial infarction, and dementia. Many affected individuals are asymptomatic or have non-specific symptoms, and prior research reported that roughly 62% of people with AFib were unaware of the condition before diagnosis. Because AFib can remain undetected until complications occur, there is interest in identifying earlier, noninvasive markers of increased risk.
A recent analysis published in PLOS Digital Health explored whether retinal imaging could reveal signals associated with future AFib. The investigators accessed retinal images from two large cohorts — AlzEye and the U.K. Biobank — and analyzed over 90,000 optical coherence tomography (OCT) scans and color retinal photographs. The retina offers a unique, noninvasive window on microvasculature and neural tissue; OCT and fundus photography allow measurement of retinal layer thickness and vascular features that may reflect systemic vascular or neurodegenerative processes.
Lead author Josef Huemer, MD, noted that the retina is the only site where blood vessels and nerve fiber tissue can be examined noninvasively with commonly available eye tests such as OCT scans and fundus photographs. The study team applied image analysis and segmentation approaches to quantify retinal layer thicknesses and compare findings between people with and without AFib.
Across the analyzed datasets, people with AFib showed consistent thinning of the macular ganglion cell and inner plexiform layer (mGCIPL). The mGCIPL combines the ganglion cell layer, which transmits visual information from the retina to the brain, and the inner plexiform layer, which processes signals like motion and luminance changes. The authors interpret thinning of the mGCIPL as a marker of retrograde, or past, degeneration rather than a disease-specific change.
The researchers also observed thinning of the inner nuclear layer. Unlike the mGCIPL thinning, the inner nuclear layer change is not readily explained by retrograde degeneration; the authors hypothesize it may reflect direct vulnerability to microvascular ischemic events within the eye.
Huemer highlighted that the mGCIPL thinning was detected in both cohorts — a hospital-based set and a population volunteer cohort — strengthening confidence that the association is robust across different sample types.
Importantly, the study identified retinal thinning prior to clinical recognition of AFib. Among participants who did not have AFib at the time retinal images were obtained, those who later developed AFib had thinner mGCIPL layers on average about 4 years before presenting to hospital with the arrhythmia. The authors emphasize two implications: first, the diagnostic challenge of AFib (often delayed or missed), and second, the availability of OCT scans in routine eye care settings where quantitative layer thickness measurement is feasible.
The biological pathways linking AFib with retinal structural change are not fully delineated. The study team and independent experts suggested plausible mechanisms. One hypothesis is that AFib predisposes to cerebral and ocular microembolic events or “mini strokes” that produce retrograde degeneration and thinning of retinal neurons. Another possibility is that intermittent or subtle ischemia related to cardiovascular disease causes damage to retinal tissue directly. The retina’s high metabolic demand and sensitivity to impaired perfusion make it a plausible site to reveal systemic microvascular injury.
Experts quoted in the report stressed that while structural retinal changes are a plausible downstream signal of vascular compromise, the precise causal relationships and specificity for AFib versus other cardiovascular or neurological conditions remain to be clarified.
If validated, retinal imaging markers could expand opportunities for earlier risk stratification. Routine eye imaging performed in optometry and ophthalmology settings — including high street optometrists who perform OCT — could potentially identify individuals at elevated risk of AFib who might benefit from targeted cardiovascular evaluation, including extended electrocardiogram monitoring.
Interventional cardiology and ophthalmology clinicians not involved in the study commented that a technique that flags people at increased AFib risk via routine ocular imaging could improve detection and referral pathways, though they emphasized the need for further research to define predictive performance and clinical utility.
The investigators report ongoing work to expand OCT-related image analysis, enlarge oculomic datasets, and advance algorithms toward regulatory approval for medical-device use in local optometry settings. They aim to refine automated approaches for earlier detection of systemic disease from retinal images. The study authors and external commentators agree that future research must determine the exact biological changes in the eye that associate with AFib, validate predictive accuracy in independent cohorts, and assess whether retinal markers improve risk calculation beyond established cardiovascular risk factors.
Limitations noted in the discussion include the need for further validation and clarification of mechanisms; specific methodological details, subgroup analyses, and statistical metrics were reported in the original paper and are not repeated here. Overall, the findings support the concept that retinal OCT and fundus imaging may provide noninvasive biomarkers for systemic cardiovascular conditions such as AFib, and they justify further prospective and translational work to evaluate clinical implementation.